{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Leeds+North+West&min-ddpCreated=2018-05-01T20%3A03%3A48.807Z&ddpModified.=2019-02-04T23%3A25%3A28.766Z&max-date=2019-07-18", "items" : [{"_about" : "http://data.parliament.uk/resources/1054660", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1054660/answer", "answerText" : {"_value" : "<p>The Department has no plans currently. The National Institute for Health and Care Excellence is currently developing guidance on Brineura (Cerliponase alfa) for treating neuronal ceroid lipofuscinosis type 2 under the highly specialised technology programme. Further information can be found at the following link:<\/p><p> <\/p><p><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-hst10008\" target=\"_blank\">https://www.nice.org.uk/guidance/indevelopment/gid-hst10008<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-12T15:49:07.43Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cerliponase Alfa"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care,  if he will hold meetings with families of children with ceroid lipofuscinosis type 2 disease on the availability of Brineura on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "216384"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}